Glenn Schulman, PharmD, MPH CONTACT: Investor Contact: SVP, Corporate Communications & IR
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally. ABOUT AURINIA
View source version on businesswire.com:https://www.businesswire.com/news/home/20210726005060/en/ The conference call and webcast is scheduled for August 5, 2021 at 4:30 p.m. ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under “News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
SOURCE: Aurinia Pharmaceuticals Inc. Copyright News Wire 2021. INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
KEYWORD: NORTH AMERICA CANADA email@example.com
The News Highlights
- Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on Aug 5, 2021 | The business
- Check the latest News news updates and information about business, finance and more.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week